Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer

Prostate

Volumn 36, Issue SUPPL. 8, 1998, Pages 52-61

  Aprikian, Armen G ^a   Han, Kehan ^a   Guy, Laurent ^a   Landry, France ^a   Begin, Louis R ^a   Chevalier, Simone ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Bombesin; Gastrin releasing peptide; Human prostate cancer; Neuroendocrine phenotype

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ADENOSINE TRIPHOSPHATE; BOMBESIN; BOMBESIN RECEPTOR; CHROMOGRANIN A; FIBRONECTIN; FOCAL ADHESION KINASE; GASTRIN RELEASING PEPTIDE; GENISTEIN; LAMININ; NEUROPEPTIDE; PHOSPHOTYROSINE; PROSTATE SPECIFIC ANTIGEN; RC 3095; VITRONECTIN; CELL ADHESION MOLECULE; FOCAL ADHESION KINASE 1; PROTEIN TYROSINE KINASE; PTK2 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR DIFFERENTIATION; CELL DIFFERENTIATION; DISEASE COURSE; MALE; METABOLISM; NEUROSECRETION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

BOMBESIN; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; DISEASE PROGRESSION; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GASTRIN-RELEASING PEPTIDE; HUMANS; MALE; NEUROSECRETORY SYSTEMS; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 26844555865     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(1998)8+<52::AID-PROS9>3.0.CO;2-I     Document Type: Article

References (29)

1. Ballentine CH, Coffey DS: The prostate: An increasing medical problem. Prostate 1990;16:39-48.
2. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L: Peptide-hormone- and serotonin-immunoreactive tumor cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298-307.
3. di Sant'Agnese PA, de Mesy Jensen KL: Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987;18:849-856.
4. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:3952-3965.
5. Aprikian AG, Cordon-Cardo C, Fair WR, Zhang ZF, Bazinet M, Hamdy S, Reuter VE: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 1994;151:914-919.
6. di Sant'Agnese PA, Cockett AT: Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-361.
7. Abrahamsson PA, Falkmer S, Falt K, Grimelius L: The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker." Pathol Res Pract 1989;185:373-380.
8. Kadmon D, Thompson TC, Lynch GR, Scardino PT: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;146:358-361.
9. Woll PJ: Neuropeptide growth factors and cancer. Br J Cancer 1991;63:469-475.
10. Zachary I, Woll PJ, Rozengurt E: A role for neuropeptides in the control of cell proliferation. Dev Biol 1987;124:295-308.
11. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-1720.
12. Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J: Bombesin specially induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996;16:297-306.
13. Hoosein NM, Logothetis CJ, Chung LWK: Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
14. Aprikian AG, Tremblay L, Han K, Chevalier S: Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer 1997;72:498-504.
15. Milovanovic SR, Radulovic S, Groot K, Schally AV: Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. Prostate 1992;20:269-280.
16. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV: Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 1997;32:164-172.
17. Cutz E, Gillan JE, Track NS: Pulmonary endocrine cells in the developing human lung and during neonatal adaptation. In Becker KL, Gazdar AF (eds): "Endocrine Lung in Health and Disease." Philadelphia: WB Saunders, 1984, pp 210-231.
18. Chen RJ, Glezerson G, Taylor LF, Grundle HAJ, Naude JH: The neuroendocrine cell population of the human prostate gland. J Urol 1993;150:365-368.
19. Bonkoff H, Stein V, Remberger K: Multidirectional differentiation in the normal, hyperplastic and neoplastic human prostate: Simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994;25:42-46.
20. Tutton PJM, Barkla DH: Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells. Anticancer Res 1987;7:1-12.
21. Stridsberg M, Fabiani R, Lukinius A, Ronquist G: Prostasomes are neuroendocrine-like vesicles in human semen. Prostate 1996;29:287-295.
22. Bonkoff H, Wernert N, Dhom G, Remberger K: Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19:91-98.
23. Cohen RJ, Glezerson G, Haffejee Z: Neuro-endocrine cells - A new prognostic parameter in prostate cancer. Br J Urol 1991;68:258-262.
24. Krijnen JLM, Bogdanowicz JFAT, Seldenrijk CE, Mulder PGH, Van Der Kwast TH: The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171-174.
25. Weinstein MH, Partin AW, Veltri RW, Epstein JI: Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression following radical prostatectomy. Hum Pathol 1996;27:683-687.
26. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG: Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987;59:1803-1809.
27. Cohen MK, Arber DA, Coffield KS, Keegan GT, McClintock J, Speights VO Jr: Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994;74:1899-1903.
28. Noordzij MA, Van Der Kwast TH, Van Steenbrugge GJ, Hop WJ, Schroeder FH: The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-258.
29. Stratton M, Evans DJ, Lambert IA: Prostatic adenocarcinoma evolving into carcinoid: Selective effect of hormonal treatment. J Clin Pathol 1986;39:750-756.